LXRX
Lexicon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.24
−0.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 41.5M | 49.8M | 31.1M | 1.2M | 139.0K |
| Cost of Revenue | 476.0K | 274.0K | 616.0K | 59.0M | 52.5M |
| Gross Profit | 41.0M | 49.5M | 30.5M | (57.8M) | (52.4M) |
| Operating Expenses | |||||
| R&D Expense | 60.2M | 61.1M | 84.5M | 58.9M | 52.8M |
| SG&A Expense | 35.3M | 37.3M | 131.9M | — | — |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 11.2M | 55.1M | (4.4M) |
| Total Operating Expenses | 95.5M | 98.4M | 227.6M | 114.0M | 48.4M |
| Cost and Expenses | 96.0M | 98.7M | 228.2M | 173.0M | 100.9M |
| Operating Income (EBIT) | (54.5M) | (48.9M) | (197.1M) | (171.8M) | (100.8M) |
| Non-Operating | |||||
| Interest Income | 6.1M | 6.9M | 12.3M | 7.7M | 1.6M |
| Interest Expense | 8.4M | 8.3M | 15.6M | 13.1M | 2.8M |
| Net Interest Income | (2.3M) | (1.4M) | (3.3M) | (5.4M) | (1.2M) |
| Other Non-Op Income/Expense | (6.6M) | (1.4M) | (3.3M) | (5.4M) | (1.2M) |
| Non-Operating Income (excl Interest) | (1.8M) | (6.9M) | (12.3M) | (1.4M) | (300.0K) |
| EBT (Pre-Tax Income) | (61.1M) | (50.3M) | (200.4M) | (177.1M) | (101.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (61.1M) | (50.3M) | (200.4M) | (177.1M) | (101.9M) |
| Earnings from Cont. Ops | (61.1M) | (50.3M) | (200.4M) | (177.1M) | (101.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (61.1M) | (50.3M) | (200.4M) | (177.1M) | (101.9M) |
| Per Share | |||||
| Basic EPS | ($0.15) | ($0.14) | ($0.63) | ($0.80) | ($0.62) |
| Diluted EPS | ($0.15) | ($0.14) | ($0.63) | ($0.80) | ($0.62) |
| Revenue Per Share | $0.09 | $0.14 | $0.10 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 437.7M | 363.1M | 320.0M | 221.1M | 165.7M |
| Diluted Shares Outstanding | 437.7M | 363.1M | 320.0M | 221.1M | 165.7M |
| Profitability Metrics | |||||
| EBITDA | (52.3M) | (41.4M) | (184.3M) | (169.8M) | (100.0M) |
| D&A | 481.0K | 621.0K | 534.0K | 554.0K | 427.0K |
| EBIT | (52.7M) | (42.0M) | (184.8M) | (170.3M) | (100.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026